ArticleJournal of inflammation research2025
The Predictive Value of the Neutrophil Percentage-to-Albumin Ratio for Early Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Preprocedural systemic immune-inflammation index predicts atrial fibrillation recurrence after catheter ablation: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The neutrophil percentage-to-albumin ratio (NPAR) serves as a robust prognostic indicator for adverse cardiovascular events. This pioneering study is the first to examine the relationship between the NPAR and post-ablation atrial fibrillation (AF) recurrence in patients undergoing radiofrequency catheter ablation (RFCA). Patients and Methods: In this retrospective analysis, 394 treatment-naïve AF patients undergoing initial RFCA were enrolled and stratified into recurrence and non-recurrence cohorts. The study utilized four composite inflammatory indices as biomarkers: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and NPAR. Cox proportional hazards regression modeling was employed to assess the prognostic significance of post-ablation AF recurrence following RFCA. Receiver operating characteristic (ROC) curve analysis evaluated the discriminative capacity of inflammatory biomarkers, utilizing area under the curve (AUC) quantification as the principal measure for prognostic stratification accuracy. Results: With a median follow-up duration of 12.00 months, early AF recurrence occurred in 88 cases (22.34%), demonstrating significantly higher incidence rates in patients with elevated NPAR levels. Univariate Cox regression identified significant associations between AF recurrence and inflammatory indices (NLR, PLR, SII, NPAR), persistent AF phenotype, heart failure status, age, serum creatinine levels, left ventricular ejection fraction (LVEF), B-type natriuretic peptide (BNP) levels, and left atrial diameter (LAD) (all P < 0.05). Multivariable analysis demonstrated NPAR, persistent AF, and LAD as independent predictors of post-ablation recurrence (adjusted P < 0.05). ROC curve analysis demonstrated superior predictive performance of the NPAR for AF recurrence compared to SII, PLR, and NLR, with AUC of 0.706 (P < 0.01; 95% CI: 0.642-0.770). Kaplan-Meier survival analysis demonstrated significantly increased 1-year AF recurrence rates among patients with elevated NPAR levels exceeding 15.36 (log-rank P < 0.01). Conclusion: The NPAR represents a promising novel biomarker for risk stratification of post-ablation AF recurrence in patients undergoing RFCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.